Technological advancements, rise in prevalence of cancer, and increase in genome mapping programs and number of R&D activities drive the growth of the global epigenetics market.
Technological advancements, rise in prevalence of cancer, and increase in genome mapping programs and number of R&D activities drive the growth of the global epigenetics market. However, standardization concerns regarding epigenetics-based diagnostics and lack of skilled professionals hamper the market growth. On the contrary, untapped potential in developing countries is expected to create lucrative opportunities for the market players in the future.
Global Epigenetics Market was estimated at $772 million in 2019 and is expected to hit $2.16 billion by 2027, registering a CAGR of 13.6% from 2020 to 2027.
Download Detailed COVID-19 Impact Sample Report at:
https://www.alliedmarketresearch.com/request-for-customization/846?reqfor=covid
High-end technological advancements associated with epigenetics, rise in incidences of cancer, surge in genome mapping programs, and growing number of R&D activities drive the global epigenetics market. On the other hand, standardization concerns over epigenetics-based diagnostics and dearth of skilled professionals impede the growth to some extent. However, several growth opportunities in the emerging economies have created an array of lucrative prospects for the key players in the industry.
The academic and research institutes segment to register the highest CAGR through 2027
By end user, the academic and research institutes segment is anticipated to manifest the highest CAGR of 14.5% from 2020 to 2027, as high-throughput and massive parallelization of next-generation sequencing have influenced researchers to sequence entire genomes of different organisms, ranging from humans to microorganisms. However, the pharmaceutical and biotechnology companies segment contributed the largest share in 2019, holding more than half of the global epigenetics market, as these companies have invested in epigenetic research to understand the complex pattern of drug resistance developed by microorganisms, oncology, molecular aspects of cancer, and drug discovery.
Based on geography, North America garnered the major share in 2019, generating nearly two-fifths of the global epigenetics market. Simultaneously, Asia-Pacific would portray the fastest CAGR of 14.7% throughout the forecast period. The other two regions studied in the report include Europe and LAMEA.
The kits segment held the lion’s share
By product, the kits segment held the largest share in 2019, accounting for nearly two-fifths of the global epigenetics market, owing to increase in the aging population, rise in incidences of chronic diseases, and growth in adoption of epigenetic procedures. However, the instruments segment is expected to register the highest CAGR of 15.5% during the forecast period, due to surge in research, innovation, & development across different laboratory settings.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/846
North America dominated the market
By region, the market across North America held the lion’s share in 2019, accounting for nearly two-fifths of the market, due to significant developments in biotechnology through epigenetics products, rise in investments, and increase in partnerships & collaborations among key players. However, the global epigenetics market across LAMEA is projected to portray the highest CAGR of 15.5% during the forecast period.
Major market players
- Abcam Plc.
- Agilent Technologies, Inc.
- Active Motif, Inc.
- Illumina Inc.
- Diagenode, PerkinElmer, Inc.
- Merck Millipore
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Zymo Research
Allied Market Research Coverage on the Healthcare Domain
Medical Videoscope Market by Product Type (Videoscopes and Visualization & Documentation Systems), Application (Bronchoscopy, Arthroscopy, Laparoscopy, Urology Endoscopy, Neuroendoscopy, Gastrointestinal Endoscopy, Obstetrics/Gynecology Endoscopy, ENT Endoscopy, and Others), and End User (Hospitals, Clinics, and Others) - Global Opportunity Analysis and Industry Forecast, 2021-2028
Breast Biopsy Market by Product [Vacuum Assisted Biopsy (VAB), Core Needle Biopsy (CNB) and Fine Needle Aspiration Biopsy (FNAB)], Image Guided Technology (MRI-Guided Biopsy, Ultrasound Guided Biopsy, Mammography Guided Stereotactic Biopsy, CT-Guided Biopsy) and End User (Hospitals and Diagnostic Centers) - Global Opportunity Analysis and Industry Forecast, 2020-2027
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com